



Jerry Katzman

Emeritus New York Medical, USA

An Affordable 200 degree non-mydratiac retinal microcamera (RETINALCAM) is capable of imaging the peripheral retina to detect early signs of diabetic retinopathy (DR) for mass screening.

The earliest sign of diabetes shows in the peripheral retina. As DR is the most common cause of global blindness early detection is attained by examination of the peripheral retina. A Long before DR and Diabetic Macula Edema (DME) manifest prevention of progression may be achieved by early treatment preventing vision loss. Currently early detection of DR requires a visit to an ophthalmologist for a dilated exam. The RETINALCAM is suitable for the general practitioner and medical clinics. Since the onset of the current pandemic tele-medicine has been widely accepted and utilized. The above MICROCAM designed for office use has been modified for home monitoring. The RETINALCAM is a patient home monitoring system that allows the patient to self- monitor the high definition image to the doctor's office. The system is not only for ophthalmologists and optometrists but includes all medical sub-specialties. Once pathology has been detected continuous remote management may be used. The home monitoring system is a revolutionary enhancement of the microcam that contributes a major contribution to patient management.

Biography

Jerry Katzman is the Company's Chief Executive Officer, President, and Chairman of the Board of Directors. Katzman has always been an entrepreneur, scientist, and pioneer in medical science. His focus has targeted various biotechnology companies, biopharma, and Wall Street. Upon completion of his medical training, Katzman joined a multi-specialty group practice in Brandon, FL where he founded and established the group's department of ophthalmology. Katzman graduated from Boston University with a B.S. in Biomedical Engineering in 1974 and thereafter earned his M.D. from the Universidad de Guadalajara in Jalisco, Mexico